This announcement is made by JHBP (CY) Holdings Limited (the “Company”, together with itssubsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

SHANGHAI, China, December 28, 2020 - Genor Biopharma Co Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, announced today that multiple IND applications of GB491 (cyclin-dependent kinase 4/6 inhibitor) are under review by NMPA, including indications for 1L/2L hormone receptor positive / human epidermal growth factor receptor 2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.

SHANGHAI, China, Nov 4, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, announced that its New Drug Application (NDA) for its infliximab biosimilar GB242 to National Medical Products Administration (NMPA) is under review. Genor submitted NDA on October 27 2020 and NMPA accepted on the NDA on November 3 2020, which again demonstrated strong execution capabilities of Genor team.

SHANGHAI, China, Oct. 27, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, announced today that it has submitted New Drug Application (NDA) for its infliximab biosimilar GB242 to National Medical Products Administration (NMPA).

JHBP (CY) Holdings Limited (“Genor Biopharma” or the “Company”; stock code: 6998.HK), a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs, was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) at 9:00am today, with a board lot of 500 Shares each.